Evommune (EVMN) Fundamental Analysis: Revenue, Earnings & Valuation

4.11 / 10

Netural

Fundamental score is 4.11/10, indicating modest health. Strengths include high inventory turnover, receivables turnover, fixed‑asset efficiency, and favorable Revenue‑MV and PB‑ROE. Weaknesses are low revenue growth, poor asset‑MV, high cost‑of‑sales ratio and thin interest coverage.

Analysis Checks(8/10)

Revenue-MV

Value-0.08

Score3/3

Weight34.87%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value85.71

Score0/3

Weight-7.49%

1M Return-2.75%

Inventory turnover ratio

Value106.57

Score3/3

Weight-1.98%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score3/3

Weight7.17%

1M Return2.33%

PB-ROE

Value1.34

Score2/3

Weight39.09%

1M Return8.98%

Income tax / Total profit (%)

Value22.35

Score2/3

Weight12.07%

1M Return3.20%

Fixed assets turnover ratio

Value6.10

Score3/3

Weight2.61%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.21%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-2.17%

1M Return-0.74%

Asset-MV

Value-0.55

Score0/3

Weight18.03%

1M Return4.88%

Is EVMN fundamentally strong?

EVMN scores 4.11/10 on fundamentals and holds a Fair valuation at present. Backed by its -54.42% ROE, -529.77% net margin, -12.10 P/E ratio, 4.05 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.